Navigation Links
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Date:10/8/2007

cramps. Neupro(R) improved sleep quality, reduced excessive daytime sleepiness, decreased night-time urinary symptoms (nocturias), and appeared generally well-tolerated. The most frequently reported adverse events in patients treated with Neupro(R) were application site reactions (20%), nausea (19%), and somnolence (11%).

Additionally, new, interim safety data from a four-year, open-label extension of a separate pivotal Phase III, double-blind clinical trial were presented. These data, in 216 patients with early-stage Parkinson's disease, showed Neupro(R) was generally well-tolerated at 33 months of treatment. Patients were tapered to their Neupro(R) starting dose and re-titrated over a 3-week period. Neupro(R) doses were limited to <6 mg/24 hours the first year, after which doses <16 mg/24 hours were allowed.

The majority of participants (73%) remained in the study at 33 months, with few discontinuations related to adverse events (13%) and a low incidence of dyskinesia (6.5%). The most frequently reported adverse events among patients treated with Neupro(R) in this trial were somnolence (41%), application site reactions (23%), most of which were rated as mild (95%), nausea (18%) and dizziness (20%).

"We are pleased to present important data which help demonstrate the benefits of Neupro in patients with early and advanced-stage Parkinson's disease," said Iris Loew-Friedrich, MD, PhD, Global Head of Development, UCB. "We look forward to continuing the Neupro clinical development program and are working to make this unique therapy available for U.S. patients with advanced stages of the disease."

About Neupro(R)

Neupro(R), with the active ingredient rotigotine, is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery system, a patch, designed for once-a-day application. Neupro(R) is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. The system is ap
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
2. NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
5. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
8. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
9. Gabapentin Shown Effective for Fibromyalgia Pain
10. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
11. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... , July 30, 2014 /PRNewswire-iReach/ -- This ... Global and Chinese Heparin sodium (CAS 9041-08-1) & ... the basic information of Heparin sodium (CAS 9041-08-1) ... and manufacturing technology. The report then explores global ... 9041-08-1) & calcium (CAS 37270-89-6) listing their product ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. ... company management will participate in the Jefferies 2014 Boston ... , Massachusetts. The conference will occur on August 6, 2014 ... BioPharma, Inc. PDL BioPharma manages a portfolio ... Queen et al. antibody humanization patents and license agreements ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 ... substantially during the five years to 2014. Following a ... thanks to beneficial demographic trends, the expansion of private ... result, IBISWorld estimates that Hearing Aid Clinics industry ... 3.4% to $2.7 billion during the five years to ...
(Date:7/30/2014)... 2014 The global market for hearing ... 2020, growing at an estimated CAGR of 3.2% from ... Grand View Research, Inc. Growing global base of geriatric ... to serve this market as a primary growth driver. ... hearing aid technology and patient awareness levels are expected ...
(Date:7/30/2014)... who have the most common genetic mutation linked to ... overweight or obese people who do not have the ... the Endocrine Society,s Journal of Clinical Endocrinology & ... of adults are obese. Obesity typically results from a ... activity and genetics. In particular, consumption of appetizing foods ...
(Date:7/30/2014)... an Ohio teen who died of a caffeine overdose ... well-tolerated and mass-consumed substance. To help prevent serious health ... scientists are reporting progress toward a rapid, at-home test ... most beverages and even breast milk. Their report appears ... . , Mani Subramanian and colleagues note that caffeine,s ...
(Date:7/30/2014)... McKinney, Texas (PRWEB) July 30, 2014 ... surgical hospital, is proud to announce the launch of ... throat (ENT), and general surgery. The doctors working in ... the needs of infants, children, and adolescents. Dr. Timothy ... Kapadia, Dr. Chad McDuffie, Dr. Neelesh Mehendale, and Dr. ...
Breaking Medicine News(10 mins):Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3
... children with the most common form of childhood cancer ... the cancer cells survive their best efforts and the most ... scientists led by researchers at the University of California, San ... a protein that leukemia cells use to stay alive. Targeting ...
... May 18 (HealthDay News) -- Women who smoke during pregnancy ... a DNA change, a new study suggests. The change, ... researchers argue that the altered genes, which can be passed ... more likely than others to develop certain diseases, such as ...
... antigen) level over several years which had been seen ... recently come under fire as a screening test because it ... A new study, however, shows nearly 70 percent of ... were eventually diagnosed with prostate cancer, according to research from ...
... Minn. -- Mayo Clinic has developed a ... for Lynch syndrome ( http://www.mayoclinic.com/health/lynch-syndrome/DS00669 ), a ... particularly for colorectal cancer. An estimated 3 ... to Lynch syndrome. At least 80 percent ...
... products can be high in harmful saturated fat but not ... of thousands of adults in Costa Rica found that their ... their risk of a heart attack. "Things like milk ... community health graduate student at Brown University and the lead ...
... Jefferson and an international team of collaborators have discovered ... women will respond to anti-estrogen therapy. The research ... Journal of Clinical Oncology . Anti-estrogen drugs, most notably ... breast cancer. However, as many as a third of ...
Cached Medicine News:Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3Health News:When Pregnant Mom Smokes, Baby's DNA May Change 2Health News:When rising PSA means prostate cancer is in patient's future 2Health News:New Mayo Clinic test targets Lynch syndrome, a risk factor for colon cancer 2Health News:Dairy consumption does not elevate heart-attack risk, study suggests 2Health News:Marker identifies breast cancer patients likely to respond to tamoxifen 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: